A physician emphasized how emotional support, reliable health information and caregiver involvement can encourage men to take a more proactive approach to prostate cancer screening and care.
|Articles|April 21, 2015
Dr. Primo Lara Discusses Emerging Therapies in Kidney Cancer
Primo Neary Lara Jr., associate director of Translational Research at the UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.
Advertisement
Primo Neary Lara Jr., associate director of Translational Research and co-leader of the Cancer Therapeutics Program at UC Davis Comprehensive Cancer Center, discusses emerging therapies for patients with kidney cancer.
Advertisement
Related to this article
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
Advertisement
Advertisement
Trending on CURE
1
5 Years of Pancreatic Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
The Breast Cancer Test Many Patients Don’t Know to Ask For
3
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
4
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
5